NACDS, NCPA Commend US Reps for Expressing Concerns with FUL Lists

Published Online: Friday, December 16, 2011
The National Association of Chain Drug Stores (NACDS) and National Community Pharmacists Association (NCPA) commended US Representatives Bruce Braley (D-IA), Mike Rogers (R-MI) and 38 of their colleagues who expressed serious concerns with draft Federal Upper Limits (FUL) lists that have been recently published by the Centers for Medicare & Medicaid Services (CMS).

“We are concerned that these lists contain flawed information that is not reliable for use in establishing pharmacy reimbursement in Medicaid. We ask that you direct states not to use these draft lists for reimbursement purposes until they can be improved and finalized through a formal notice of proposed rule,” the members of Congress wrote in a letter to CMS.

NACDS and NCPA also expressed concern with the draft FUL lists in written comments to CMS back in October. “We are heartened that our arguments have been given further credibility by a large, bipartisan group of Representatives,” stated NACDS President and Chief Executive Officer Steven C. Anderson, IOM, CAE and NCPA CEO B. Douglas Hoey, RPh, MBA, in a statement. “We want to especially thank Representatives Braley and Rogers for their leadership on this important issue.”

In addition to urging CMS to cease publication of draft FUL lists until a final AMP rule is in place, the Representatives also urged the agency to be mindful of comprehensive pharmacy reimbursement. “When setting pharmacy reimbursement rates both components of reimbursement—product cost and cost to dispense—must be taken into consideration when determining whether pharmacies are paid adequately,” the members of Congress wrote.

To read the letter from Braley and Rogers, click here.
Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$